


Velagliflozin proline

Cat. No.:	HY-109018A		
CAS No.:	1539295-26-5		
Molecular Formula:	C ₂₈ H ₃₄ N ₂ O ₇		
Molecular Weight:	510.58		
Target:	SGLT		
Pathway:	Membrane Transporter/Ion Channel		
Storage:	Pure form	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (195.86 mM; Need ultrasonic)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	1.9586 mL	9.7928 mL	19.5856 mL
5 mM	0.3917 mL	1.9586 mL	3.9171 mL
10 mM	0.1959 mL	0.9793 mL	1.9586 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Velagliflozin proline is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin proline reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations [1].

In Vivo

Velagliflozin (1 mg/kg; p.o.; single dose) proline increases cholesterol, albumin, beta-hydroxybutyrate (BHB), nonesterified fatty acids (NEFA), and urinary glucose excretion, and decreases respiratory exchange ratio in cats^[1].
 Velagliflozin (0.3 mg/kg; p.o.; once daily for 18 d) proline is well tolerated and can improve insulin disorders and prevent laminitis in ponies by reducing the high insulin response of dietary non-structural carbohydrates (NSC)^[2].
 MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

-
- Patent. US20200352968A1.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Hoenig M, et al. Effects of the sodium-glucose cotransporter 2 (SGLT2) inhibitor velagliflozin, a new drug with therapeutic potential to treat diabetes in cats. J Vet Pharmacol Ther. 2018 Apr;41(2):266-273.
- [2]. Meier A, et al. The sodium-glucose co-transporter 2 inhibitor velagliflozin reduces hyperinsulinemia and prevents laminitis in insulin-dysregulated ponies. PLoS One. 2018 Sep 13;13(9):e0203655.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA